AKRON - Michael E. Kelly, MD, PhD, joined Akron Children’s Hospital as chief research officer on May 1. Dr. Kelly oversees the Rebecca D. Considine Research Institute and research activities conducted enterprise wide, directing the process to define the vision, clinical trial strategy and management of research studies conducted within the Akron Children’s system.
Dr. Kelly comes to Akron Children’s with over 30 years of experience in pediatric research and oncology. He is a board certified pediatric oncologist with special interests in pediatric research and the care of children and young adults diagnosed with leukemia, lymphoma and vascular tumors/anomalies. He most recently served as the medical director of the pediatric cancer program at Children’s Hospital of Wisconsin and associate professor at the Medical College of Wisconsin.
Actively involved with investigator-initiated and industry-sponsored research studies, Dr. Kelly was most recently research unit leader for the Children’s Hospital of Wisconsin Research Institute and co-director of the Pediatric BioBank and Analytical Tissue Core at Children’s Hospital of Wisconsin. He also served as director of the Pediatric Cancer Clinical Trials Office for the Department of Pediatrics, Hematology/Oncology/BMT at the Medical College of Wisconsin and member of the Clinical Research Executive Committee for the Medical College of Wisconsin’s Cancer Center. Previously, he held research appointments as institutional principle investigator for Children’s Oncology Group (COG) and the COG Phase 1 and Pilot Consortium.
Dr. Kelly served as fellowship program director for pediatrics, hematology/oncology/BMT for the Medical College of Wisconsin; medical director for pediatric hematopoietic progenitor cell transplantation; and attending physician for pediatrics hematology/oncology at Cardinal Glennon Children’s Hospital in St. Louis, MO; attending physician for pediatrics hematology/oncology at St. Louis Children’s Hospital and assistant professor of pediatrics, hematology and oncology at St. Louis University School of Medicine.
“I am personally very excited to have Dr. Kelly join us,” said Robert McGregor, MD, chief medical officer for Akron Children’s. “His successful recruitment followed a national search which led to his selection as our number one choice from a talented pool of candidates. Our internal search team believes he has not only the right skill-set including prior experience as a funded researcher and research program developer, but is a great cultural fit to drive and support our research enterprise.”
Dr. Kelly received his doctorate in developmental biology and his medical degree from the University of Cincinnati College of Medicine. His pediatrics residency and fellowship in pediatric hematology/oncology were completed at St. Louis Children’s Hospital, Washington University School of Medicine in St. Louis, MO.
Dr. Kelly holds national leadership and committee positions, including serving as a member of the Children’s Oncology Group’s Voting Body, AML New Drug Development Committee and Membership Committee; member of the American Society of Pediatric Hematology/Oncology’s Vascular Anomalies Consortium Development Committee; committee member for the Coalition for Pediatric Medical Research’s Pediatric Oncologists to Inform Cancer Moonshot Initiative; and research grant reviewer for St. Baldrick’s Foundation and Alex’s Lemonade Stand Foundation.
He has also received several awards and honors. Since 2011, he has been on the Best Doctors in America List and he was honored as one of the Best Doctors by Milwaukee Lifestyle Magazine in 2014, the same year he received the Service Excellence award from Children’s Specialty Group. His other notable awards include the Professional of the Year award representing pediatric hematology and oncology from Cambridge Who’s Who in 2011 and being named one of Southeast Wisconsin’s Best Doctors in 2010.
Dr. Kelly is originally from Zanesville and will reside in downtown Akron.